{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:51:55Z","timestamp":1791568315005,"version":"4.3.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tumoral calcinosis (TC), a rare disease characterized by calcified mass formation in peri-articular soft tissue, manifests clinically as fractures, pain, and limited range of motion. In hemodialysis patients, severe hypercalcemia and hyperphosphatemia are major causes of the condition, and correcting these metabolic disorders reportedly induces its regression. Herein, we report the case of a 46-year-old man on maintenance hemodialysis who developed TC that regressed following etelcalcetide therapy despite the absence of severe hyperphosphatemia. The patient had started hemodialysis at age 32, and soft tissue calcifications were first noted two years later. These progressed to TC, which caused a left femoral shaft fracture 13 years after the initiation of dialysis. When the fracture occurred, TC was present in both thighs and the left elbow. Seven months after the fracture, he was referred to our department. Laboratory findings showed serum phosphate, corrected calcium, and intact parathyroid hormone levels of 4.9\u00a0mg\/dL, 10.3\u00a0mg\/dL, and 109 pg\/mL, respectively. Cinacalcet was switched to intravenous etelcalcetide hydrochloride, and significant regression of the remaining TC was observed six months after the switch. Our findings suggest that etelcalcetide may be effective for TC in patients on hemodialysis, even in the absence of severe hypercalcemia or hyperphosphatemia. However, further reports are required to determine whether this observation is generalizable.<\/jats:p>","DOI":"10.1007\/s13730-026-01181-8","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:41:07Z","timestamp":1791520867000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regression of uremic tumoral calcinosis following the switch from cinacalcet to etelcalcetide in a hemodialysis patient without severe hyperphosphatemia"],"prefix":"10.1007","volume":"15","author":[{"given":"Takuya","family":"Hase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Oe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-1068","authenticated-orcid":false,"given":"Hideki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"issue":"2","key":"1181_CR1","first-page":"379","volume":"26","author":"F Cofan","year":"1999","unstructured":"Cofan F, Garc\u00eda S, Combalia A, Campistol JM, Oppenheimer F, Ram\u00f3n R. Uremic tumoral calcinosis in patients receiving longterm hemodialysis therapy. J Rheumatol. 1999;26(2):379\u201385.","journal-title":"J Rheumatol"},{"issue":"3","key":"1181_CR2","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1148\/rg.263055099","volume":"26","author":"KM Olsen","year":"2006","unstructured":"Olsen KM, Chew FS. Tumoral calcinosis: pearls, polemics, and alternative possibilities. Radiographics. 2006;26(3):871\u201385. https:\/\/doi.org\/10.1148\/rg.263055099.","journal-title":"Radiographics"},{"issue":"3","key":"1181_CR3","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1053\/ajkd.2003.50139","volume":"41","author":"SJ Kim","year":"2003","unstructured":"Kim SJ, Goldstein M, Szabo T, Pierratos A. Resolution of massive uremic tumoral calcinosis with daily nocturnal home hemodialysis. Am J Kidney Dis. 2003;41(3):e121\u20137. https:\/\/doi.org\/10.1053\/ajkd.2003.50139.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"1181_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5935\/0101-2800.20170037","volume":"39","author":"ME Maioli","year":"2017","unstructured":"Maioli ME, Delfino VDA, Guerra ACDZ, Kunii LF, Frange RFN. Reversal of uremic tumoral calcinosis by optimization of clinical treatment of bone and mineral metabolism disorder. Jornal Brasileiro de Nefrologia. 2017;39(2):217\u20139. https:\/\/doi.org\/10.5935\/0101-2800.20170037.","journal-title":"Jornal Brasileiro de Nefrologia"},{"issue":"3","key":"1181_CR5","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/1744-9987.12035","volume":"17","author":"S Yamada","year":"2013","unstructured":"Yamada S, Tsuruya K, Kitazono T. Regression of tumoral calcinosis after the appropriate control of a deranged mineral and bone metabolism, in conjugation with cinacalcet hydrochloride treatment, in a chronic hemodialysis patient. Ther Apher Dial. 2013;17(3):348\u20139. https:\/\/doi.org\/10.1111\/1744-9987.12035.","journal-title":"Ther Apher Dial"},{"key":"1181_CR6","doi-asserted-by":"publisher","unstructured":"Moral Berrio E, Cox Conforme RA, El\u00edas R, De La Flor JC, Rodr\u00edguez Tudero C, S\u00e1nchez de la Nieta-Garc\u00eda MD, Zamora Gonz\u00e1lez-Mari\u00f1o R, Vozmediano Poyatos C. An unusual case of uremic tumoral calcinosis with atypical manifestation in a patient on peritoneal dialysis: case report and review of the literature, case report and review of the literature. Med Sci (Basel). 2025;13(1):11. https:\/\/doi.org\/10.3390\/medsci13010011","DOI":"10.3390\/medsci13010011"},{"issue":"3","key":"1181_CR7","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1542-4758.2012.00760.x","volume":"17","author":"S Sunder","year":"2013","unstructured":"Sunder S, Verma H, Venkataramanan K. Cervical tumoral calcinosis with secondary hyperparathyroidism in a chronic hemodialysis patient. Hemodial Int. 2013;17(3):458\u201362. https:\/\/doi.org\/10.1111\/j.1542-4758.2012.00760.x..","journal-title":"Hemodial Int"},{"issue":"3","key":"1181_CR8","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3747\/pdi.2018.00212","volume":"39","author":"A Hayat","year":"2019","unstructured":"Hayat A. Complete resolution of tumoral calcinosis in a patient on peritoneal dialysis with cinacalcet. Perit Dial Int. 2019;39(3):292\u20133. https:\/\/doi.org\/10.3747\/pdi.2018.00212.","journal-title":"Perit Dial Int"},{"key":"1181_CR9","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1681\/ASN.V1341017","volume":"13","author":"WG Goodman","year":"2002","unstructured":"Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Barri YM, Cohen RM, Coburn JW. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol. 2002;13:1017\u201324. https:\/\/doi.org\/10.1681\/ASN.V1341017.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"1181_CR10","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.ekir.2017.01.016","volume":"2","author":"K Yokoyama","year":"2017","unstructured":"Yokoyama K, Fukagawa M, Shigematsu T, Akiba T, Fujii A, Yamauchi A, Odani M, Akizawa T, ONO-5163 Study Group. A single- and multiple-dose, multicenter study of etelcalcetide in japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int Rep. 2017;2(4):634\u201344. https:\/\/doi.org\/10.1016\/j.ekir.2017.01.016.","journal-title":"Kidney Int Rep"},{"key":"1181_CR11","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/ki.2008.407","volume":"74","author":"T Kawata","year":"2008","unstructured":"Kawata T, Nagano N, Obi M, Miyata S, Koyama C, Kobayashi N, Wakita S, Wada M. Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Kidney Int. 2008;74:1270\u20137. https:\/\/doi.org\/10.1038\/ki.2008.407.","journal-title":"Kidney Int"},{"key":"1181_CR12","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","volume":"26","author":"P Raggi","year":"2011","unstructured":"Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J, ADVANCE Study Group. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transpl. 2011;26:1327\u201339. https:\/\/doi.org\/10.1093\/ndt\/gfq725.","journal-title":"Nephrol Dial Transpl"},{"key":"1181_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/IJNRD.S54731","volume":"7","author":"K Nakayama","year":"2013","unstructured":"Nakayama K. Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism. Int Int J Nephrol Renovasc Dis. 2013;7:25\u201333. https:\/\/doi.org\/10.2147\/IJNRD.S54731.","journal-title":"Int Int J Nephrol Renovasc Dis"},{"issue":"2","key":"1181_CR14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.5371\/hp.2022.34.2.122","volume":"34","author":"SS Park","year":"2022","unstructured":"Park SS, Yim SJ, Park SH. Pathologic fracture of femoral neck in a patient with tumoral calcinosis. Hip Pelvis. 2022;34(2):122\u20136. https:\/\/doi.org\/10.5371\/hp.2022.34.2.122.","journal-title":"Hip Pelvis"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-026-01181-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-026-01181-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-026-01181-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:03:28Z","timestamp":1791565408000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-026-01181-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":14,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1181"],"URL":"https:\/\/doi.org\/10.1007\/s13730-026-01181-8","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"10 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.F. has received lecture fees from Kyowa Kirin. S.G. has received lecture fees from Kyowa Kirin.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this case report in accordance with institutional policies.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have obtained consent from the patient discussed in the report.","order":3,"name":"Ethics","label":"Patient consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"147"}}